Cholestyramine (Questran) for Lymphocytic Colitis
Cholestyramine can induce remission in lymphocytic colitis, particularly when bile acid malabsorption is present, with response rates of 60-75% in clinical studies, though it is not recommended as first-line therapy by current guidelines.
Guideline Recommendations
The 2016 AGA guidelines specifically address cholestyramine in microscopic colitis (which includes lymphocytic colitis). The AGA suggests against combination therapy with cholestyramine and mesalamine over mesalamine alone (Recommendation 6, conditional recommendation, low quality evidence) 1. Critically, the guideline panel explicitly states: "The panel is not able to comment on the appropriateness of cholestyramine monotherapy in the absence of clinical trials that have evaluated that intervention" 1.
The AGA strongly recommends budesonide as first-line therapy for inducing clinical remission in symptomatic microscopic colitis (strong recommendation, moderate quality evidence) 1.
The 2021 European guidelines on microscopic colitis acknowledge bile acid sequestrants as a treatment option, though specific positioning relative to other therapies requires consideration of individual patient factors 2.
Clinical Evidence Supporting Cholestyramine
Despite the guideline's inability to formally recommend cholestyramine monotherapy, substantial research evidence demonstrates its effectiveness:
Efficacy in Lymphocytic Colitis
A 2004 Belgian study showed 75% of lymphocytic colitis patients achieved good clinical effect with cholestyramine as first-line therapy, with rapid onset of anti-diarrheal effect within one week 3.
A 2001 Spanish study found that 60% of lymphocytic colitis patients had bile acid malabsorption (BAM), compared to only 27% with collagenous colitis 4. Among those with BAM, cholestyramine induced clinical remission in 19 of 22 patients with microscopic colitis 4.
A 2023 Mayo Clinic study of 282 patients with microscopic colitis treated with bile acid sequestrants (primarily cholestyramine) found 49.3% complete response and 16.3% partial response, totaling nearly two-thirds with meaningful improvement 5.
Key Clinical Insights
The mechanism appears related to bile acid malabsorption: Lymphocytic colitis has higher rates of BAM than collagenous colitis (60% vs 27%), suggesting cholestyramine addresses an underlying pathophysiologic mechanism rather than just providing symptomatic relief 4.
Response is independent of bile acid testing: The Mayo Clinic study found that bile acid testing (done in only 31.9% of patients) did not predict response to therapy 5. This suggests empiric trials of cholestyramine are reasonable without requiring confirmatory testing.
Dosing does not correlate with response: The Mayo study found no association between BAS dose and clinical response 5, suggesting standard dosing is appropriate.
Clinical Algorithm
When to Consider Cholestyramine:
Second-line therapy when budesonide is not feasible due to:
- Cost considerations
- Contraindications to corticosteroids
- Patient preference to avoid steroids
Empiric trial in lymphocytic colitis patients with chronic watery diarrhea, given the high prevalence of BAM (60%) 4
Combination with mesalamine may be considered for collagenous colitis specifically, though evidence is mixed 6
Expected Timeline:
- Clinical response typically occurs within 1 week of initiating therapy 3
- Formal assessment should occur at 12 ± 4 weeks 5
Maintenance Considerations:
- After discontinuation, 41.6% experience recurrence at median 21 weeks 5
- Long-term maintenance may be necessary in responders
Important Caveats
Drug interactions are significant: Cholestyramine binds other medications and can interfere with absorption. Patients must take other drugs at least 1 hour before or 4-6 hours after cholestyramine 7. This is particularly problematic in older populations with polypharmacy, which influenced the AGA's conditional recommendation against combination therapy 1.
Fat-soluble vitamin deficiency: Long-term use requires monitoring and supplementation with vitamins A, D, E, and K 7.
Constipation: The most common adverse effect, which may require dose adjustment 7.
Intolerance rate: Approximately 9.6% discontinue due to side effects 5.
Bottom Line
While budesonide remains the guideline-recommended first-line therapy, cholestyramine represents an effective alternative for lymphocytic colitis, particularly given the high prevalence of bile acid malabsorption in this subtype. The evidence supports its use as monotherapy despite the absence of formal guideline endorsement, with response rates comparable to other second-line agents and a favorable safety profile when drug interactions are managed appropriately.